Plasma pTau 217/β-amyloid 1–42 ratio for enhanced accuracy and reduced uncertainty in detecting amyloid pathology
Brain · 07.04.2026 · 149 (4) · 1168-1181
DOI: 10.1093/brain/awag001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, online erschienen am 21.01.2026. Verfasst von Natalya Benina und 19 weiteren Autor:innen. Beteiligte Einrichtung: Fujirebio Diagnostics, Inc., Malvern, PA 19355, USA. Hauptthemen laut MEDLINE: Amyloid beta-Peptides, Peptide Fragments, tau Proteins, Alzheimer Disease. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Swedish Brain Foundation, NIA NIH HHS, Family Rönström.
Abstract (Originalsprache)
Blood biomarkers have the potential to revolutionize Alzheimer's disease diagnosis, offering advantages over CSF and PET due to their accessibility, scalability and cost-effectiveness. This study evaluated the effectiveness of individual plasma biomarkers, such as phosphorylated Tau (pTau) 217, as well as biomarker combinations, with a focus on the pTau 217/β-Amyloid (Aβ) 1–42 ratio to predict amyloid positivity. To improve clinical utility, a dual threshold approach was applied to maximize predictive values and positive likelihood ratios while minimizing the proportion of indeterminate results. Plasma samples from 208 participants (including seven with subjective cognitive decline, 150 with mild cognitive impairment, 12 with Alzheimer's disease dementia and 39 with other cognitive conditions) from three cohorts (BioFINDER2, BIOCARD and MissionAD) were analysed to measure Aβ1–42, Aβ1–40 and pTau217 levels using the Fujirebio LUMIPULSE® G1200 platform. Amyloid status was determined by FDA-cleared PET imaging and/or CSF biomarker ratios. Logistic regression modelling evaluated biomarkers either individually or in combination to identify those that best distinguished amyloid positivity. Clinically applicable thresholds were established through likelihood ratio analysis and further evaluated based on predictive values. When assessing the ability of individual plasma biomarkers to differentiate between amyloid-positive and amyloid-negative participants, plasma pTau217 (P < 0.001) and plasma Aβ1–42 (P = 0.0056) demonstrated significant discriminative power, whereas Aβ1–40 (P = 0.30) did not. Notably, the integration of these biomarkers into the plasma pTau217/Aβ1–42 ratio demonstrated enhanced classification performance (P < 0.001). Using a two-threshold approach based on positive and negative likelihood ratios (PLR/NLR) targets of 14/20, respectively, the plasma pTau217/Aβ1–42 ratio achieved a positive predictive value (PPV) of 94.44% and negative predictive value (NPV) of 94.28%, in the parametric model, comparable to plasma pTau217 alone (PPV: 94.44%, NPV: 94.28%), but yielded fewer indeterminate results (26.5% versus 38.6%). Using a non-parametric model, the plasma ratio achieved a PPV and NPV of 94.62% and 91.78%, respectively, while plasma pTau217 alone achieved 92.41% and 92.86%; the ratio once again reduced the proportion of indeterminate results (20.2% versus 35.1%). The plasma pTau217/Aβ1–42 ratio demonstrated superior performance in identifying amyloid pathology and reduced the frequency of indeterminate results compared to plasma pTau217 alone. These findings support the evaluation of the clinical utility of the plasma pTau217/Aβ1–42 ratio as a tool for identifying amyloid pathology in patients presenting with cognitive complaints.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Fujirebio Diagnostics, Inc., Malvern, PA 19355, USA.
- Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.
- Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund 221 00, Sweden.
- Memory Clinic, Skane University Hospital, Malmö 205 02, Sweden.
- VU University Medical Center, Department of Neurology and Alzheimer Center, Amsterdam Neuroscience, Amsterdam 1081 HV, The Netherlands.
- Department of Clinical Chemistry and Pharmacology, Skåne University Hospital, Lund 221 85, Sweden.
ORCID-Profile: Niklas Mattsson-Carlgren, Sebastian Palmqvist, Oskar Hansson
Förderung
- Swedish Brain Foundation
- NIA NIH HHS
- Family Rönström
- Kamprad Foundation
- Bundy Academy and MultiPark
- Swedish Alzheimer Foundation
- Michael J. Fox Foundation
- Lund University
Zitieren
APA
Benina, N., Buitrago, L., De Simone, F. I., Radwan, R. R., Miller, M. C., Martin, K., Dickson, D., Ho, S., Moghekar, A., Albert, M., Mattsson-Carlgren, N., Palmqvist, S., Ossenkoppele, R., Jonsson, M. F., Hansson, O., Stomrud, E., Sachdev, P., Niu, H., Verbel, D., & Hawkins, D. M. (2026). Plasma pTau 217/β-amyloid 1–42 ratio for enhanced accuracy and reduced uncertainty in detecting amyloid pathology. Brain, 149(4), 1168-1181. https://doi.org/10.1093/brain/awag001
Vancouver
Benina N, Buitrago L, De Simone FI, Radwan RR, Miller MC, Martin K, et al. Plasma pTau 217/β-amyloid 1–42 ratio for enhanced accuracy and reduced uncertainty in detecting amyloid pathology. Brain. 2026;149(4):1168-1181. doi:10.1093/brain/awag001
BibTeX
@article{Benina2026,
author = {Benina, Natalya and Buitrago, Luna and De Simone, Francesca I and Radwan, Rachel R and Miller, M Craig and Martin, Katie and Dickson, Diana and Ho, Sara and Moghekar, Abhay and Albert, Marilyn and Mattsson-Carlgren, Niklas and Palmqvist, Sebastian and Ossenkoppele, Rik and Jonsson, Magnus Förnvik and Hansson, Oskar and Stomrud, Erik and Sachdev, Pallavi and Niu, Hongmei and Verbel, David and Hawkins, Douglas M},
title = {Plasma pTau 217/β-amyloid 1–42 ratio for enhanced accuracy and reduced uncertainty in detecting amyloid pathology},
journal = {Brain},
year = {2026},
volume = {149},
number = {4},
pages = {1168--1181},
doi = {10.1093/brain/awag001}
}
EUVIMED